

Cynata Therapeutics Advances Patent Estate in Australia and Canada for Cymerus™ Patent Application

Melbourne, Australia; 17 October 2022: Cynata Therapeutics Limited (ASX: “CYP” or “Cynata”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that a Notice of Acceptance has been received from IP Australia for a patent application, entitled “Colony Forming Medium and Use Thereof” covering its proprietary Cymerus™ mesenchymal stem cell (MSC) technology. A Notice of Allowance has also been received from the Canadian Intellectual Property Office (CIPO) in respect of the same application and also for a further patent application entitled “Pluripotent Stem Cell Assay”.

The patent applications are all wholly-owned by Cynata and describe important aspects of the Company’s unique cell therapy manufacturing processes.

Dr Ross Macdonald, Cynata’s Chief Executive Officer, said:

“Cynata’s robust intellectual property portfolio encompassing the Cymerus therapeutic stem cell platform technology continues to grow and strengthen, further reinforcing the Company’s position as the global leader in the development of induced pluripotent stem cell (iPSC) derived cell therapies. These further patents support our proprietary method of manufacturing MSCs which enables efficient manufacture of therapeutic MSCs at scale with consistent quality and without requiring multiple donors. We look forward to the continued development of our patent estate as the Company also advances its clinical programs in multiple therapeutic areas of high unmet medical need.”

The Notice of Acceptance is sent to the applicant when IP Australia (i.e. the Australian Government’s patent agency) intends to issue a patent. Cynata anticipates that the Australian patent will be granted by late January 2023, with an expiration date of 14 March 2037. Similarly, the CIPO Notice of Allowance is sent to the applicant when the CIPO intends to issue a patent. The Canadian patents are expected to be granted by mid-January 2023, with an expiration date of 14 March 2037, with respect to the first application described above, and by 15 November 2037, with respect to the second application.

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119 343, ross.macdonald@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, littlebigdealconsulting@gmail.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Planning for a Phase 2 clinical



trial in GvHD under a cleared US FDA IND is presently underway. Clinical trials of Cymerus products in osteoarthritis (Phase 3) and diabetic foot ulcers (DFU) are currently ongoing. In addition, Cynata has demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.